For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Steroid | Topical corticosteroid : prednisolone phosphate 1% with preservative four times a day for 1 week, BID for 1 week, QD for 1 week Antibiotics : moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization | None | None | 15 | 250 | 44 | 250 | View |
| Placebo | Placebo : 0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, BID for 1 week, QD for 1 week Antibiotics : moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization | None | None | 13 | 250 | 34 | 250 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Increase in hypopyon | None | Eye disorders | None | View |
| Increase in infiltrate size >50% | None | Eye disorders | None | View |
| No healing of epithelial defect by 21 days | None | Eye disorders | None | View |
| Intraocular pressure (IOP) elevated >25mm Hg by <35 mm Hg | None | Eye disorders | None | View |
| Progressive corneal thinning | None | Eye disorders | None | View |
| Other | None | General disorders | None | View |